Clinical trials: Healthy Skin
Healthy, Psoriasis
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
The proposed exploratory study aims to understand the in vivo skin distribution properties of subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow microperfusion (OFM).
- Trial name
- OFM ISF (NCT01539213)
- Testing
- secukinumab (AIN457)
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.
- Trial name
- NCT03419910
- Testing
- BMS-986165, Cyclosporine
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. There were 3 dose cohorts (75mg, 90mg, 105mg) with 12 healthy subjects in each cohorts (6 males and 6 females).
- Trial name
- Hemay005 (NCT04837235)
- Testing
- Hemay005
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Systemic Lupus Erythematosus
Japanese phase1 Study of Belimumab (IV vs SC)
This study is an open-label, randomized, 2 parallel group, single dose study in healthy Japanese males to assess the pharmacokinetics and safety/tolerability of single intravenous administration and single subcutaneous…
- Trial name
- NCT01516450
- Testing
- GSK1550188 IV, GSK1550188 SC
- Where
- Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Psoriasis
Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT2206 Injection vs Stelara® (EU-licensed and US-licensed) in healthy Chinese male…
- Trial name
- NCT04371185
- Testing
- BAT2206, Stelara(US-licensed), Stelara(EU-licensed)
- Where
- China
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Primary Immune Thrombocytopenia
The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
A randomized, double-blind, placebo-controlled, single-ascending dose, phase Ia study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamics, and immunogenicity of STSA-1301 Subcutaneous Injection in healthy…
- Trial name
- NCT06148389
- Testing
- STSA-1301 subcutaneous injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hyperhidrosis
A Non-Interventional Study To Assess Sweating
To evaluate the gravimetric sweat measurements in subjects who meet the subjective criteria for a diagnosis of palmar hyperhidrosis compared to subjects without hyperhidrosis.
- Trial name
- NCT02552199
- Testing
- gravimetric
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Botanix Pharmaceuticals
Psoriasis
Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT2306 Injection vs Cosentyx® (EU-licensed and US-licensed) in healthy Chinese…
- Trial name
- NCT04711343
- Testing
- BAT2306, Cosentyx (US-licensed), Cosentyx (EU-licensed)
- Where
- China
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Skin Health
Efficacy of a Nutritional Supplement on Skin Health in Generally Healthy Adults
Consumption of dietary supplements has been found to modulate skin health. Individual ingredients such as collagen peptides, lutein and ceramides have been shown to improve skin health.
- Trial name
- NCT03771807
- Testing
- Beauty From Within, Facial cleansing
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Psoriasis
A Study of SHR-1314 in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, single dose escalating, study in 5 sequential cohorts to investigate the effect of a single s.c.
- Trial name
- NCT02934412
- Testing
- SHR-1314
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Healthy
Clinical Evaluation of the Photoallergy Potential of Atralin Gel
To assess the potential of tretinoin gel 0.05% and its vehicle to produce photoallergic reactions, measured as skin reactions following induction and challenge.
- Trial name
- NCT00603772
- Testing
- Atralin (tretinoin) gel, 0.05%
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Coria Laboratories, Ltd.
Skin
A Study to Evaluate the Effect of Lycomato on Skin Attributes in Healthy Participants.
The study will be performed with oral gels, with up to 55 study subjects who meet the inclusion and non-inclusion criteria required.
- Trial name
- NCT05328388
- Testing
- Lycomato
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- LycoRed Ltd.
Diabetic Foot
BE Study of Metformin GSK 500mg
A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fasting condition. It is a pivotal study.
- Trial name
- BA/BE 173/11 (NCT01710527)
- Testing
- Metformin 500mg, Glucophage 500mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers
MRG-110 is intended to promote the growth of new blood vessels by inhibiting a molecule called miR-92a. MRG-110 is being studied to determine if it can accelerate healing of wounds by improving blood flow into the wound area.
- Trial name
- NCT03603431
- Testing
- MRG-110
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- miRagen Therapeutics, Inc.
Visible Light Exposure on Healthy Back Skin
Photoprotection Efficacy of Different Topical Agents Under Visible Light Exposure
To evaluate the protective effect of seven sunscreens on the pigmentation induced by visible light in comparison to an untreated control zone in healthy volunteers
- Trial name
- NCT06796153
- Testing
- Visible Light Exposure - Treated zones, Visible Light Exposure - Untreated zone
- Where
- Romania
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Healthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected Skin
Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.
Study objective To assess the performance of different application regimens of Actinica® on protection from UV rays-induced erythema throughout 1 day of sun exposure in fair-skinned healthy subjects (phototype I to III).
- Trial name
- NCT02251756
- Testing
- Actinica, 0.8 mg/cm2, 1 application, Actinica, 0.8 mg/cm2, 2 applications, Actinica, 2 mg/cm2, 1 application
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Irritation Potential of Topic Agent
A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers
This is a Phase I single-site study to evaluate the irritation potential of topically applied ATx201 GEL, 2% and 4%, along with positive and negative control and placebo control (ATx201 GEL Placebo), in healthy human subjects on…
- Trial name
- NCT03301870
- Testing
- ATx201 Gel 2%, ATx201 Gel 4%, Positive Control
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- UNION therapeutics
Rheumatoid Arthritis
A Multiple Dose of HL237 in Healthy Male Subject
HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic structure of biguanide in metformin, an existing diabetes drug. The immune modulating activity of HL237 was demonstrated in animal model.
- Trial name
- NCT03896594
- Testing
- HL237
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Healthy Volunteers
A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
A study to demonstrate the safety and tolerability of AZD1163 when administered intravenously and subcutaneously in healthy participants.
- Trial name
- NCT06103877
- Testing
- AZD1163
- Where
- 3 sites in United States, Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acne Vulgaris
Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%
To evaluate the therapeutic equivalence of topical Adapalene Gel, 0.1 % and Differin®(Adapalene) Gel, 0.1 % in the treatment of acne vulgaris and to demonstrate the superiority of the efficacy of the test and reference products…
- Trial name
- NCT04329403
- Testing
- Adapalene 0.1% Gel, Differin 0.1% Topical Gel
- Sponsor
- Aurobindo Pharma Ltd